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cause of renal failure. For several decades, ADPKD was regarded as an adult-onset disease. In the past
decade, it has become more widely appreciated that the disease course begins in childhood. However,
evidence-based guidelines on how to manage and approach children diagnosed with or at risk of ADPKD
are lacking. Also, scoring systems to stratify patients into risk categories have been established only for
adults. Overall, there are insufficient data on the clinical course during childhood. We therefore initiated
the global ADPedKD project to establish a large international pediatric ADPKD cohort for deep
characterization.
Methods: Global ADPedKD is an international multicenter observational study focusing on childhood-
diagnosed ADPKD. This collaborative project is based on interoperable Web-based databases,
comprising 7 regional and independent but uniformly organized chapters, namely Africa, Asia, Australia,
Europe, North America, South America, and the United Kingdom. In the database, a detailed basic data
questionnaire, including genetics, is used in combination with data entry from follow-up visits, to provide
both retrospective and prospective longitudinal data on clinical, radiologic, and laboratory findings, as well
as therapeutic interventions.
Discussion: The global ADPedKD initiative aims to characterize in detail the most extensive international
pediatric ADPKD cohort reported to date, providing evidence for the development of unified diagnostic,
follow-up, and treatment recommendations regarding modifiable disease factors. Moreover, this registry
will serve as a platform for the development of clinical and/or biochemical markers predicting the risk of
early and progressive disease.
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International Reports (2019) 4, 1271–1284A DPKD is the most common monogenic cause ofrenal failure, and therefore constitutes a sub-
stantial worldwide socioeconomic health concern. This
multiorgan disorder arises due to gene mutations in the
PKD genes: PKD1, in up to 85% of cases, and PKD2, in
approximately 15% of cases, encoding the polycystin
proteins PC1 and PC2, respectively.1 Recently, muta-
tions in GANAB and DNAJB11 have been described to
cause rare, atypical forms of ADPKD.2,31271
CLINICAL RESEARCH S De Rechter et al.: ADPedKDADPKD is typically characterized by bilateral, pro-
gressive cyst formation and growth in all nephron
segments, often leading to end-stage kidney disease.
Although there is substantial individual variability in
phenotypic severity,4 there are clear renal phenotype
progression patterns associated with differing genetic
backgrounds. Indeed, adults with PKD2 mutations are
more mildly affected compared with patients with
PKD1. Among the latter, carriers of truncating muta-
tions are more seriously affected than nontruncating
mutation carriers.5 Evidence has been published
demonstrating interventions that slow disease pro-
gression in adults: the vasopressin-2-receptor antago-
nist tolvaptan,6 and meticulous attention to blood
pressure.7,8
Importantly, ADPKD is not an isolated renal disease,
as patients may display a broad range of extrarenal
phenotypes, including polycystic liver disease,
inguinal hernias, intracranial aneurysms, and cardiac
valve abnormalities.9,10 The current consensus holds
that extrarenal manifestations are rare in childhood;
however, this has not been rigorously studied, and our
registry will address this gap in knowledge.
For several decades, ADPKD was regarded as an
adult-onset disease, but initial cyst formation starts in
utero.11 Possible symptoms, such as urinary concen-
tration defects, hypertension, and proteinuria, have
been described in childhood.12–18 Moreover, early
intervention needs to be considered to attenuate long-
term renal and extrarenal complications.19 Guidelines
unfortunately are lacking with regard to children
diagnosed with ADPKD,20 and more controversially,
those asymptomatically at risk for ADPKD based on
family history,21 as shown in a recently performed
survey of European caregivers.22 Diagnostic, follow-
up, and treatment protocols for childhood ADPKD are
therefore very heterogeneous, despite several initia-
tives undertaken to standardize patient care, namely
the Kidney Disease: Improving Global Outcomes
(KDIGO) consensus, the first initiative to provide clin-
ical practice guidelines on the management of
ADPKD,23 the European ADPKD Forum (EAF) Re-
ports,24,25 and the Australasian Kidney Health
Australia–Caring for Australasians with Renal Impair-
ment (KHA-CARI) guidelines,26 and the very recently
published international consensus statement.27
Strikingly, for most medical conditions, there is still
a significant discrepancy regarding data obtained in
adults versus children, explaining our current
relative ignorance with regard to pediatric ADPKD
(Table 128–71). Moreover, the available data are often
obtained from small cohorts, as neither long-term nor
large cohorts of children affected by ADPKD have been
published. The Colorado Registry published cohort1272data with retrospective follow-up of up to 16 years
(Supplementary Table S1), but some results should be
carefully interpreted, as at-risk children were included
and regarded as non-ADPKD when they had no renal
cysts on ultrasound before the age of 18 years even if
the disease was not ruled out by genetic analysis.17,28,72
As illustrated in Supplementary Table S1, diagnostic
criteria for childhood ADPKD are highly variable,
leading to incomparable study groups and results.
Scoring systems to stratify patients into risk cate-
gories for end-stage kidney disease development,
mainly based on height-adjusted total kidney volume
(htTKV)73 and ADPKD genotype,5 have been devel-
oped for adult patients.67–69 In children, no progres-
sion markers have been validated yet, although some
are suggested, such as the appearance of very early
onset polycystic kidney disease. In this group, in
whom ADPKD is diagnosed in utero or within the first
18 months of life, clinical outcomes are worse
compared with non–very early onset ADPKD.60 Other
clinical or biochemical risk makers have not yet been
established for childhood ADPKD, nor have screening
and treatment approaches. This demonstrates the need
for a large pediatric cohort in which these and other
relevant factors will be studied. This is of growing
importance, as ADPKD-affected children are increas-
ingly regarded as candidates for early treatment of
modifiable morbidities, as well as for future therapies,
once available.11,19 Therefore, we have aimed to
initiate the global ADPedKD registry to build a large,
longitudinal international childhood-diagnosed
ADPKD cohort, detailing with both renal and extra-
renal disease manifestations and including familial
and genetic data.METHODS
Aim of the Study
Global ADPedKD is an international, multicenter,
observational study, including both retrospective and
prospective longitudinal data. As data on pediatric
ADPKD are scarce, the study is designed to generate
data on its prevalence and presentation in childhood,
and of its comorbidities, such as hypertension, left
ventricular hypertrophy, and proteinuria. Thereby,
we aim to provide an observational evidence base for
the development of unified diagnostic, follow-up, and
treatment recommendations to slow disease progres-
sion. Second, our goal is to establish clinical markers
predicting the risk of early progressive disease, and
thus to combine disease progression factors for pedi-
atric ADPKD into a pediatric scoring system. The
latter could enable caregivers to stratify patients from
an early disease stage into low to high risk categories,Kidney International Reports (2019) 4, 1271–1284
Table 1. Overview of the literature of adult versus pediatric ADPKD
Studied topic Adult ADPKD Pediatric ADPKD
Routine presymptomatic screening for
at-risk persons
Recommended25 Not recommended,25 but polarized opinion among caregivers22
Diagnostic criteria Renal ultrasound criteria28 Renal ultrasound criteria only applicable from the age of 15 yr28
Prevalence - 3.96/10,000 in Europe,29 ranging from 1:1100 to
1:30584
- 1:543 in the Seychelles (Indian Ocean)30
- 1:400 to 1:1000 in the United States31
- 1:4033 in Japan32
No reports
Renal manifestations and
complications (frequency, % of
studied patients)
- Nephromegaly (100%33)
- ESKD (50% in 6th decade4)
- Hematuria (42%34)
- Micro-albuminuria and proteinuria (19%–40% and 18%,
respectively35,36)
- Urinary tract infections (60%37)
- Back, flank, or abdominal pain (27.5%38)
- Gastrointestinal symptoms (61.2%38)
- Nephrolithiasis (28%40)
- Decreased urinary concentrating ability (100%41)
- No reports on glomerular hyperfiltration
- Cyst infection (0.01 episode per patient per yr45)
- Nephromegaly (50%15)
- Accelerated renal growth (100%15)
- ESKD rare, decreased eGFR (<90 mL/min per 1.73 m2;
12%16 to 39%15)
- Hematuria (uncommon34)
- Micro-albuminuria and proteinuria (30%–48%
and 10%–23%, respectively15–17)
- Urinary tract infections (20%39)
- Back, flank or abdominal pain (21%39)
- Nephrolithiasis (uncommon42,43)
- Decreased urinary concentrating ability (58%42,44)
- Glomerular hyperfiltration (18%46 to 21%16)
- No reports on cyst infection
Extrarenal manifestations and
complications (frequency, % of
studied patients)
- Hepatic cysts (85%–94%47)
- Hypertension before renal function decline (60%–75%49)
- LVH (50% in 40th decade51)
- Mitral valve prolapse (26%52)
- Intracranial arterial aneurysms (12.4%54)
- Inguinal/abdominal herniation (45%55)
- Common bile duct dilation (40%55)
- Pancreatic cysts (9%–36%55)
- Splenic cysts (2.7%47)
- Diverticular disease (50%–83% in patients with ESKD55)
- Arachnoid cysts (8%–12%23)
- Spinal meningeal cysts (1.7%23)
- Seminal vesicle cysts (40%23)
- Bronchiectasis (37%23)
- Hepatic cysts (uncommon48)
- Hypertension before renal function decline (20%50)
- LVH (0% although significantly higher left ventricular
mass compared with controls53)
- Mitral valve prolapse (12%42)
- Intracranial arterial aneurysms (uncommon,
only case reports56,57)
- Inguinal/abdominal herniation (16%39)
- No reports on common bile duct dilation, pancreatic cysts, splenic
cysts, diverticular disease, arachnoid cysts, spinal meningeal
cysts, seminal vesicle cysts, bronchiectasis
FDA-approved prognostic enrichment
biomarker
(ht)TKV since 201658 No reports
Validated prognostic indicators PKD genotype5
TKV33
No reports
Suggested prognostic indicators
(in bold those suggested in both
adult and pediatric populations)
Age, male sex, LBW, race, BMI, BSA, PKD genotype,
ciliopathy genes (e.g., HNF1B), low RBF, hypertension,
urologic events, chronic asymptomatic pyuria, presence of
hernia, TKV, (e)GFR, proteinuria, cholesterol, urinary
sodium excretion, urine osmolality, uric acid, thrombocyte
count, copeptin, plasma ADH, MCP-1, high caffeine intake,
high protein intake, low water intake and smoking4,59
VEO ADPKD,60–63 hypertension,12–14,49,64 glomerular
hyperfiltration,46 PKD genotype,65,66 proteinuria,17 urine
osmolality,44 presentation at diagnosis (screening versus
symptoms),15,63 and LVMI13
Patient stratification scoring systems
predicting disease progression
- PRO-PKD score, based on sex, PKD genotype, presence of
hypertension and/or urologic events <35 yr67
- Mayo Imaging Classification, based on htTKV range for age68
- ADPKD Outcomes Model, based on a disease progression
equations for htTKV and eGFR69
No reports
Evidence-based interventions to slow
down disease progression, currently
in clinical practice
- Rigorous blood pressure control with ACEi7,8
- Tolvaptan70
ACEi if blood pressure > percentile 95 for age, sex, and height23;
however, the only RCT performed in the pediatric cohort failed to
demonstrate a significant effect of ACEi on renal growth over the
5-yr study period71
ACEi, angiotensin-converting-enzyme inhibitor; ADH, antidiuretic hormone; ADPKD, autosomal dominant polycystic kidney disease; ADPKD-OM, ADPKD Outcomes Model; BMI, body
mass index; BSA, body surface area; (e)GFR, (estimated) glomerular filtration rate; ESKD, end-stage kidney disease; FDA, Food and Drug Administration; (ht)TKV, (height-adjusted) total
kidney volume; LBW, low birth weight; LVH, left ventricular hypertrophy; MCP-1, monocyte chemoattractant protein 1; PRO-PKD, predicting renal outcomes in ADPKD; RBF, renal blood
flow; RCT, randomized clinical trial; VEO, very early onset.
S De Rechter et al.: ADPedKD CLINICAL RESEARCHto determine the required intensity of follow-up and
to select patients for potential future therapies.
Particular attention will be paid to the initial pre-
sentation, prenatal and perinatal history, familial
history, genetic analysis, and longitudinal evolution
of renal function and volume. Finally, ADPedKD willKidney International Reports (2019) 4, 1271–1284generate a well-characterized cohort that will be
available for epidemiologic studies in the future, and
possibly lay the foundation for future clinical trial
patient selection. The participation of major pediatric
nephrology centers throughout Africa, Asia,
Australia, Europe, North America, South America,1273
CLINICAL RESEARCH S De Rechter et al.: ADPedKDand the United Kingdom will optimize patient
enrollment and will expedite new knowledge
transfer into clinical patient care, while harmonizing
the quality of care for this patient group globally. The
study is endorsed by University Hospitals Leuven,
the Working Group of Inherited Kidney Diseases of
the European Society of Pediatric Nephrology, the
International Pediatric Nephrology Association, the
Working Group of Inherited Kidney Diseases of the
European Renal Association–European Dialysis and
Transplant Association, and the European Reference
Network for Rare Kidney Diseases. Furthermore, the
members of the Executive Committee will engage with
local pediatric nephrology communities via local or-
ganizations in the various international regions and
jurisdictions. Another ongoing outreach effort is
through the European ADPKD Forum, and the patient
organizations PKD International (Switzerland) and
PKD Foundation (United States).
Executive Committee
ADPedKD was initiated by UZ Leuven, Djalila Mekahli,
and Max C. Liebau. The global ADPedKD platform was
initiated and coordinated by UZ Leuven, Stéphanie De
Rechter, and Djalila Mekahli. The Global Executive
Committee will be responsible for the governance of
global ADPedKD. The members are, in alphabetical
order, Detlef Bockenhauer, Stéphanie De Rechter, Lisa
M. Guay-Woodford, Max C. Liebau, Isaac Liu, Andrew
J. Mallett, Djalila Mekahli, Franz Schaefer, L.C. Syl-
vestre, and Neveen A. Soliman. These members will
also lead the Regional Operational Committees, in Af-
rica (Neveen A. Soliman), Asia (Isaac Liu), Australia
(Andrew J. Mallett), Europe (Stéphanie De Rechter,
Franz Schaefer, Max C. Liebau, and Djalila Mekahli),
North America (Lisa M. Guay-Woodford), South
America (L.C. Sylvestre), and the United Kingdom
(Detlef Bockenhauer) and coordinate the participation
of patients and centers in their region. All the data will
be protected and managed by the Executive Commit-
tee. Requests for data and/or research proposals will be
handled by the Global Executive and Regional Opera-
tional Committees. Furthermore, each participating
center is exclusively able to review the data from the
corresponding site after request.
Characteristics of Participants
Patients eligible for inclusion are individuals diagnosed
with ADPKD before the age of 19 years. Each pediatric
center will have the option to include data from their
patients who have transitioned to adult clinics. This
“transitioned” cohort will allow us to optimize our
analysis on long-term progression. The diagnosis is
defined by the presence of at least 1 renal cyst with a1274positive family history74 and/or a positive molecular
assessment of the known ADPKD genes. Also, children
diagnosed with the contiguous gene syndrome (TSC2-
PKD1) will be included and studied as a subgroup.
Patient inclusion is preceded by written informed
consent of the patient and/or their parents or legal
representatives, after approval of the study and the
related study documents, including informed consent
forms by the corresponding local ethics committee.
Patients can be included only by their treating ne-
phrologists and cannot participate directly in the reg-
istry without involvement of their treating clinician/s.
The study has been reviewed and approved by the
Ethics Committee of University Hospitals Leuven
(S59638) as the leading center and confirmed by the
local institutional review boards of all participating
centers, including the lead centers in Africa, Asia,
Australia, Europe, North America, South America, and
the United Kingdom. The study is conducted according
to the 2013 Declaration of Helsinki, the guidelines of
Good Clinical Practice, and with all applicable regula-
tory requirements, including the recently enforced
European Union General Data Protection Regulation.75
Design of the Study and Study Procedures
This global collaborative project is based on interop-
erable Web-based databases, comprising 7 regional and
independent but uniformly organized chapters, each
led by their own principal investigator, namely Africa,
Asia, Australia, Europe, North America, South Amer-
ica, and the United Kingdom. After signing the
informed consent forms, patients’ data are pseudony-
mously entered by the patient’s caregiver and/or his or
her team member(s) in the Web-based database,
accessible via https://www.adpedkd.org/. Local in-
vestigators are able to access the ADPedKD Web site at
any time for the following purposes: entering and
editing data, posing questions, and accessing center
enrollment overview. Also, the Downloads section of
the Web site gives access to all study-related docu-
ments, including a handbook, patient information, and
informed consent forms sorted per language for all
participating countries and the complete study proto-
col and ethics committee statement. Currently, we
already have 11 languages available (Dutch, English,
French [Belgium], French [France], German, Italian,
Polish, Portuguese, Romanian, Serbian, and Turkish).
Africa, Asia, and Europe share 1 common database.
Its data entry section is secured by restriction to a
personal username and password for each investi-
gator. Moreover, the use of Secure Sockets Layer
encrypted-connections ensure data protection. Only
the responsible local study site is able to identify their
own included subjects based on the identificationKidney International Reports (2019) 4, 1271–1284
Figure 1. ADPedKD study design. ICF, informed consent form.
S De Rechter et al.: ADPedKD CLINICAL RESEARCHpseudonym, and this will be protected from disclo-
sure as described in both the research protocol and
informed consent forms. Therefore, participating
centers are exclusively able to review and/or modify
data of patients from the corresponding site and are
responsible for data protection. To ensure the highest
levels of data quality, the online case report forms
require mandatory inclusion of key variables and
include automated entry checks based on predefined
plausibility ranges. Moreover, wherever possible,
values are calculated and updated automatically. For
instance: body mass index, weight standard deviation
score, height SD score, and body mass index SD score
are calculated automatically after entry of weight and
height, based on the World Health Organization
reference standards, as these can be applied to all
children regardless of ethnicity, socioeconomic status,
or type of feeding.76 Also, in case of different stan-
dard units, laboratory results are converted automat-
ically. By these precautions, the risk of data entry
errors or incomplete data is minimized. Next, data
entries will be randomly reviewed, during regular
interim analyses and for outlying values, a query will
be sent to the local investigators.
Data acquisition (Figure 1) is subdivided into 3
sections: basic data, visits (initial and follow-up), and
study termination (Table 2).Kidney International Reports (2019) 4, 1271–1284Australia and the United Kingdom have their sepa-
rate source databases, namely Australasian Registry of
Rare and genetic Kidney disease and National Registry
of Rare Kidney Diseases, which are accessible via www.
adpedkd.org or directly via www.kidgen.org.au and
http://rarerenal.org/rare-disease-groups/adpkd-rdg/,
respectively. These databases have a fully interoperable
data structure with the ADPedKD database, including a
uniform dataset. The Australasian Registry of Rare and
genetic Kidney disease is embedded within the local
KidGen Collaborative, and its Web site launch will
occur within the coming months. It is designed to be a
“node” of as well as interact with other global registry
efforts. In North America, the ADPedKD Registry will
be implemented under the auspices of the National
Institutes of Health–funded Hepato-Renal Fibrocystic
Disease database.77
Currently, the data are stored on a secure server,
managed in Köln, Germany, for the European, Asian,
African, and South American data. The National Reg-
istry of Rare Kidney Diseases (United Kingdom), United
States, and Australia have their own secure data storage
arrangements that have been established for this reg-
istry and other related registries, for example, the
ARPKD Database (United States).
Depending on the participating center, we expect
the number of children enrolled per center to range1275
Table 2. Overview of data captured in ADPedKD, including
ADPedKD Australia (via Australasian Registry of Rare and Genetic
Kidney disease), ADPKD North America (via Hepatorenal Fibrocystic
Diseases [HRFD] Database) and ADPKD UK (via National Registry of
Rare Kidney Diseases)
Basic data
1. Personal information (date of informed consent, date of
birth, sex, date of diagnosis, and initial presentation)
2. Information on pre- and perinatal periods
3. Initial diagnosis
4. Genetic information
5. Family history
Initial visit/follow-up visits
1. Patient’s status: baseline evaluation, including biometry
2. Renal manifestations, including imaging
3. Extrarenal manifestations (CV, CNS, eye, other)
4. Laboratory values (from both blood and urine samples)
5. Medication
6. Therapies, apart from medication, including RRT
7. Further developments
Study termination
Reason for termination:
- Transfer to a center not participating in ADPedKD
- Transfer to an adult nephrology department
- Withdrawal of informed consent
- Loss of follow-up
- Patient deceased
- Other
- Unknown
ADPKD, autosomal dominant polycystic kidney disease; CNS, central nervous system;
CV, cardiovascular; RRT, renal replacement therapy.
CLINICAL RESEARCH S De Rechter et al.: ADPedKDfrom a minimum of 10 to a maximum of 100, although
this is an open registry with no formal maximal num-
ber of centers and patients. The anticipated sample size
is 2000 patients.
Basic Data
Personal information on the pre- and perinatal period,
the initial diagnosis, genetic information, and a detailed
family history are documented (Figure 1, Table 2). The
latter includes a questionnaire on family history of
tuberous sclerosis complex, diabetes mellitus, intra-
cranial aneurysm, gout, colon diverticulosis, heart
valvular defects, liver cyst(s), pancreatic cyst(s), and
kidney cyst(s) other than caused by ADPKD. More-
over, for all known affected family members, including
children already included in ADPedKD (e.g., siblings
or cousins) the age at diagnosis, age at end-stage kidney
disease (if applicable), and abdominal imaging results
are queried. This enables characterization of family
phenotypes in detail.
Initial Visit/Follow-up Visits
After completion of the baseline data collection, data
can be entered in the “visits” section, starting with the
initial visit and further visits, which are suggested to
be annual (Figure 1, Table 2). The latter is generated for
the registration of clinical, radiologic, laboratory, and
other findings of the different organ systems possibly1276affected in ADPKD (kidney, liver, cardiovascular,
neurologic, eye, and others), apart from general infor-
mation, including biometry (weight, height, blood
pressure, heart rate, and Tanner staging78). The pa-
tient’s medication, even if not directly related to
ADPKD, is entered, including dosing and duration.
Other therapeutic interventions, such as cyst fenes-
tration, dialysis, nephrectomy, renal transplantation, or
other urological/surgical procedure, are noted with
date, indication, and possible complications. An iden-
tical questionnaire is then available for all follow-up
visits, to provide data on the clinical course in both a
retrospective and prospective manner. For each visit,
an open field box is provided at the end of this visit’s
section, to add user-defined comments: any further
symptoms, performed diagnostic procedures, or other
developments.
Study Termination
In case the study is terminated, date and reason for this
will be entered (Figure 1, Table 2). The patient might
have future follow-up in a pediatric nephrology center
not participating in ADPedKD, transition to adult
nephrology care, it might be the patient’s wish to
withdraw his or her informed consent, the patient
might be deceased, or the patient might be lost to
follow-up for another or unknown reason. In case of
transfer to adult nephrology departments, the local site
is asked to engage with the future center and provide
contact with the adult nephrologist. Also, if patients
subsequently participate in an adult ADPKD registry,
the registry’s name and the patient’s registry ID will be
requested. As several registries for adult ADPKD data
are ongoing, we have added a specific item “termina-
tion of the study” in case of transfer to adult
nephrology programs. The local site is asked to fill in
the future center, the contact of the nephrologist, and if
the patients will participate in an adult ADPKD regis-
try, the registry’s name and the patient’s registry ID
will be requested. This approach will allow us to trace
the patient in the future and to merge registry data in
collaboration with the adult nephrologist community.
We note that the National Registry of Rare Kidney
Diseases and Australasian Registry of Rare and Genetic
Kidney disease initiatives include patients from all the
ages on a national basis and it will be easier to track
their course in the same database.
Importantly, in case of a transfer to another pediatric
nephrology center participating in ADPedKD, the pa-
tient is not terminating the study. The local study site
then informs the destination center about the transfer
by filling in a transfer form available in this patient’s
data entry section. The destination center can accept or
decline the transfer, and in case of acceptance, theKidney International Reports (2019) 4, 1271–1284
S De Rechter et al.: ADPedKD CLINICAL RESEARCHpatient’s data will be completely transferred to the new
center, and the patient will “disappear” from the first
site. A detailed overview of all collected data is given in
the Supplementary Material.
Statistical Analysis
Initially, we will perform a descriptive analysis,
including the calculation of relative and absolute fre-
quencies for binary/categorical variables and of
mean, SD, median, interquartile range, minimum, and
maximum for the continuous variables. Further longi-
tudinal data regarding outcomes of markers of renal
function, renal size and volume, and cardiovascular
morbidity will be analyzed using appropriate statistical
methods, such as mixed modeling. Missing data will be
handled by means of multiple imputation. Also, the
aspect of multiple testing and potential sources of bias
will be examined and considered in all analyses. If
required, the distribution of variables will be
normalized by appropriate transformation. Methods
will also include multivariable adjusted linear and lo-
gistic regression analysis for cross-sectional data, and
linear regression and proportional hazards regression
for longitudinal data. Stepwise regression procedures
(P value for entry and removal set at 0.15) will be
applied to identify potential important covariables. We
will search for optimized discrimination limits for
predictive baseline factors by maximizing Youden’s
index.
DISCUSSION
The global ADPedKD initiative aims to remedy the
current paucity of information regarding pediatric
ADPKD, especially from regions other than Europe and
the United States (Table 1, Supplementary Table S1).
Patient registries are well-recognized tools to advance
epidemiological characterization of patient cohorts and
to evaluate clinical therapies.79 Future analyses of the
ADPedKD Registry will be conducted to increase the
understanding of disease progression from early disease
stages. Data gathered during the follow-up period will
be collected from clinicians worldwide and will be
valuable to help describe childhood ADPKD preva-
lence, presentation, progression, and current manage-
ment and its effect on the disease history (e.g., strict
versus standard blood pressure control) and patient
outcomes. Initial focus will be placed on undertaking a
descriptive analysis of the dataset, once enrollment
reaches 1000 patients. These initial cross-sectional an-
alyses will focus on the prevalence of renal and
extrarenal disease manifestations, the current practices
in different regions of the world regarding monitoring
and treatment. For this, data at inclusion, including
sonomorphological markers, family history, andKidney International Reports (2019) 4, 1271–1284genetics, will be analyzed. The documented prevalence
might be different from adult ADPKD prevalence,
given the controversy about testing for disease pres-
ence in minors22 and the fact that the ADPKD diagnosis
in children might have different origins: by coinci-
dence via ultrasound for another reason, or by a pre-
senting symptom such as a urinary tract infection,
hematuria, or bedwetting.44 Also, children might be
diagnosed prenatally, and in some cases because of
screening by means of renal ultrasound or genetic
analysis of the ADPKD genes on parental request.
Moreover, diagnosis of the disease and its different
renal and extrarenal manifestations might be
region-specific, as this is dependent on patients’ and
caregivers’ awareness, availability of resources, and
organization of health care.80 These will be important
confounders in our analysis of region-specific differ-
ences and their effects on outcomes.
Longer term, we will focus on longitudinal data to
assess disease progression and evaluate risk factors that
distinguish slow versus rapid disease progression.
These analyses will facilitate appropriate patient se-
lection for future clinical trials. As part of these ana-
lyses, we will assess whether hypertension of varying
grades and other possible disease features, such as
proteinuria and left ventricular hypertrophy, should
be regarded as modifiable risk factors, early treatment
of which can slow disease progression. Moreover, the
registry will provide us with the current clinical
practice regarding monitoring of hypertension and its
treatment, including the most recommended drug class
for this indication, namely angiotensin-converting-
enzyme inhibitors. As the only randomized controlled
trial evaluating the use of angiotensin-converting-
enzyme inhibitors in pediatric ADPKD in a limited
number of children did not show a treatment benefit
over a 5-year follow-up period,71 we will evaluate
angiotensin-converting-enzyme inhibitor use versus
other antihypertensive drug classes and its effect on
renal volume and function from the registry’s obser-
vational data. We will also be able to compare outcomes
of children with low blood pressure (#50th percentile
for age, sex, and height23) versus standard blood
pressure (#95th percentile for age, sex, and height23)
regardless of treatment, as this might be more relevant
than antihypertensive treatment intensity, as shown in
adults with ADPKD in the secondary analysis of HALT
PKD Study A.81 Importantly, by these means, we will
generate data not only from centers already involved in
ADPKD research, but from nephrology centers
worldwide.
Currently, we already have 379 patients registered
from 30 different centers. Another 41 centers are
currently in the preenrollment phase (Figure 2).1277
Figure 2. ADPedKD participating centers. Because inclusion of new centers is continuously growing, we mentioned the last date of production.
CLINICAL RESEARCH S De Rechter et al.: ADPedKDThe strengths of this study are (i) the focus on an
ADPKD cohort diagnosed during childhood, repre-
senting the earliest disease stages; (ii) the unique global
collaboration established, with coverage of patients
with ADPKD from infancy to young adulthood at pe-
diatric nephrology centers around the world; (iii)
the inclusion of diverse sociodemographic back-
grounds; and (iv) the possibility to characterize family
phenotypes, based on data from both pediatric patients
with ADPKD and their (adult) relatives.
However, we recognize the inevitable possibility of
selection bias. We will not be able to include1278information on undiagnosed children at risk for
ADPKD, or on pregnancies terminated for ADPKD.
Although the latter occurs only rarely in our experi-
ence, we have no incidence reported in the literature.
According to a recent patient survey, 17% of patients
with ADPKD with chronic kidney disease and 18% of
patients with ADPKD with end-stage kidney disease
would consider prenatal diagnosis or termination of
pregnancy for ADPKD.82 Such selection bias may
impact data analysis validity; however, given the
paucity of data about childhood ADPKD, we accept this
potential limitation and believe it to be outweighed byKidney International Reports (2019) 4, 1271–1284
S De Rechter et al.: ADPedKD CLINICAL RESEARCHthe numerous potential benefits inherent with such an
initiative and approach. The immediate goal of
ADPedKD is to describe current clinical practices and to
analyze the patient population that is already under care
in reference centers and tertiary hospitals. Although this
approach might bias the cohort toward more severe
cases, the lack of a validated approach for screening
asymptomatic at-risk offspring suggests that this limi-
tation is identifiable but unable to be minimized at pre-
sent without clearer understanding more broadly of
ADPKD in the pediatric age group. Moreover,
ADPedKD, like any registry study, will be limited by the
use of real-life clinical data resulting in missing, incom-
plete, or inaccurate data entry, even despite the estab-
lished automated plausibility checks. This is especially
true for retrospectively entered data. Also, laboratory
and molecular investigations are performed using mul-
tiple techniques. Finally, entering data is labor intensive
and time-consuming, jeopardizing the completeness of
reporting. Based on our beta-testing, completion of the
case report form requires approximately 1 hour per pa-
tient visit, with some variation introduced by differ-
ences in how patient data are stored at each referral
center storage. Going forward, we expect that with the
global transition to electronic health records, data entry
increasingly will be automated; however, funding will
be sought to support centers with data entry.
In summary, the global ADPedKD registry aims to
establish a large longitudinal pediatric ADPKD cohort,
which will be jointly evaluated by the partners of the
global ADPedPKD consortium.APPENDIX
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